Previous Close | 22.85 |
Open | 22.90 |
Bid | 17.15 |
Ask | 17.90 |
Strike | 97.50 |
Expire Date | 2025-01-17 |
Day's Range | 22.85 - 22.90 |
Contract Range | N/A |
Volume | |
Open Interest | 5 |
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
NORTHAMPTON, MA / ACCESSWIRE / May 9, 2024 / A 22-year-old college student who didn't feel well was treated at an urgent care facility in Baton Rouge, Louisiana and expected to recover soon. But when his symptoms worsened, he returned to the emergency ...
Unraveling the Financial Dynamics and Strategic Directions of Gilead Sciences Inc (GILD)